Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks

8. Thermo Fisher Scientific Inc. (NYSE:TMO)

Number of Hedge Fund Holdings in Q1 2025: 101

Number of Hedge Fund Holdings in Q4 2025: 113

Performance Since Cramer’s Remarks: 15%

Date/Month of Cramer’s Remarks: June 27th, 2025

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the biggest diagnostic, laboratory products, and biopharmaceutical services providers in the world. Consequently, it also has a strong exposure to the weight loss drug market. Thermo Fisher Scientific Inc. (NYSE:TMO) is responsible for manufacturing Novo Nordisk’s Wegovy weight loss drug by filling the injection pens. Over the past year, the stock is down by 4.9%, but since Cramer’s remarks, it is up by 15%. On July 23rd, Thermo Fisher Scientific Inc. (NYSE:TMO)’s share closed 9% higher. On that day, the firm reported its second-quarter earnings. As part of the release, Thermo Fisher Scientific Inc. (NYSE:TMO) raised the lower end of its annual profit per share guidance to $22.22 per share from an earlier $21.76. The firm also posted $5.36 in quarterly profit per share to beat analyst estimates of $5.22. On October 1st, Thermo Fisher Scientific Inc. (NYSE:TMO)’s stock closed 9% higher. On September 30th, the firm announced a $2.5 billion bond offering to raise funds for general corporate purposes. Here is what Cramer had said about the firm on June 27th, 2025:

“This stock is unbelievable. It was a, it’s a great company. Marc Casper does a terrific job, but we own Danaher for the Charitable Trust, and it’s as bad as Thermo Fisher. I am urging you to not buy it till we see a pickup in Chinese orders. I know that seems strange, but this stock has crushed a lot of people. It does seem like it’s bottoming, but I am not going to push it because it’s related to China, and anything related to China is bearish.”